Biolegend, 124321, Brilliant Violet 605™ anti-mouse CD274 (B7-H1, PD-L1) Antibody, 50μg

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Maier H, et al. 2007. J. Immunol. 178:2714. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC) Paterson AM, et al. 2011. J. Immunol. 187:1097. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block) Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed Murakami R, et al. 2013. PLoS One. 8:73270. PubMed Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC) Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations: Liu H, et al. 2022. Cancer Immunol Res. 10:1028. PubMed Friebel E, et al. 2020. Cell. 181(7):1626-1642.e20. PubMed Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed Willingham SB, et al. 2018. Cancer Immunol Res. 6:1136. PubMed Wu S, et al. 2021. Nat Cancer. 2:189. PubMed Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed Bryant AJ, et al. 2018. Pulm Circ. 9:2045894018823520. PubMed Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed Lau P, et al. 2022. Cell Mol Immunol. :. PubMed Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
RRID: AB_2563635 (BioLegend Cat. No. 124321)
Structure: 40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution: T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes
Ligand/Receptor: PD-1 (PDCD1)
Cell Type: B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area: Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family: Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Sharpe A, et al. 2007. Nat. Immunol. 8:239. 2. Dong H, et al. 1999. Nat. Med. 5:1365. 3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.
Gene ID: 60533
UniProt: View information about CD274 on UniProt.org
Clone: 10F.9G2
Regulatory Status: RUO
Other Names: B7-H1, PD-L1
Isotype: Rat IgG2b, κ